Millipore's EOU produces sophisticated chromatography systems and columns for world markets as part of Millipore Corporation's global supply chain initiative and contributes to the company's growth.
CEO: Sudhir Kant (President)
Revenue: Rs 136.07 crore
Start-up Year: 1988
Address: 50 A, II Stage, Peenya Industrial Area, Bangalore – 560 068
Tel.: 91-80-28396320, 28394657
Millipore India, an ISO 9001:2000 company with a turnover of over Rs 136 crore in FY 2006-07, offers Indian manufacturers of biopharmaceuticals the entire range of solutions from upstream to downstream processing of biologics- including cell/media supplements, advanced manufacturing solutions, process monitoring tools, filtration purification and chromatography solutions plus validation and process development services and training. These solutions come from the bioprocess division of the company.
The bioscience division in addition to a range of water purification systems and solutions for general filtration, protein research, genomics and drug discovery, extends its range to include gold standard reagents, media, cell lines and antibodies from Chemicon, Upstate and Linco. These are very popular in the areas of cell biology, immunodetection and drug discovery. With this, Millipore India has entered new research areas in life sciences research in cardiovascular and infectious diseases, oncology, matrix biology, cytokines, neuroscience, metabolic disorders and signal transduction. These are supported by a group of PhDs at Millipore's technology support group.
The lab water purification range continues to make more breakthroughs- both in market dominance and in new innovations. The Advantage Milli-Q A10 with Q-Pod was a new breakthrough in water delivery systems. Millipore remains the only company to offer qualification services for both large and small systems.
The first bioprocess validation and process development facility in the country has established its extractables lab while completing the maximum number of filter validation studies in India. Millipore's predominant position in processing monoclonal antibodies with its unique expertise has been consolidated further. More than 400 pharma professionals have undergone training at Millipore's Filtration Schools.
The manufacturing operations at Millipore's EOU produces sophisticated chromatography systems and columns for world markets as part of Millipore Corporation's global supply chain initiative and contributes to the company's growth.
The most significant strategic step forward for the benefit of customers has been the spate of new acquisitions by Millipore Corporation. Serologicals- with its group companies Celliance, Chemicon, Upstate, Linco and NovAseptic, NovAseptum, Newport and Microsafe plus an alliance with Genprobe has transformed Millipore from a filtration and purification leader to a $1.5-billion science company with perhaps the widest offering of products, services, tools and technologies.